Filing Details
- Accession Number:
- 0001012975-20-000275
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-03 17:52:57
- Reporting Period:
- 2020-02-28
- Accepted Time:
- 2020-03-03 17:52:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1744659 | Akero Therapeutics Inc. | AKRO | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1278411 | S Corey Goodman | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1329161 | J Robert Adelman | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1634632 | L.p. Ii Fund Strategic Global Venbio | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1729408 | Venbio Global Strategic Gp Ii, Ltd. | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1729409 | Venbio Global Strategic Gp Ii, L.p. | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-28 | 5,100 | $21.30 | 3,212,667 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2020-03-02 | 10,297 | $23.06 | 3,202,370 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2020-03-03 | 6,401 | $23.00 | 3,195,969 | No | 4 | S | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.08, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $23.49, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- The number of shares reported in Column 5 has been reduced by 10,000 to correct a clerical error in the Reporting Person's Form 4 filed on February 12, 2020 and February 27, 2020.
- These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.
Billionaire Hedge Funds
